Coronary artery ectasia prediction: the role of the Intermountain Risk Score in identifying patients at risk.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-04-01 Epub Date: 2025-03-24 DOI:10.1080/17520363.2025.2483158

Şahhan Kilic, Süha Asal, Mert Babaoğlu, Samet Yavuz, Mohaddeseh Davoudi Bilehsavar, Hatice Altınışık, Yusuf Turan Gül, Mustafa Oğuz, Selami Doğan, Ahmet Lütfullah Orhan

{"title":"Coronary artery ectasia prediction: the role of the Intermountain Risk Score in identifying patients at risk.","authors":"Şahhan Kilic, Süha Asal, Mert Babaoğlu, Samet Yavuz, Mohaddeseh Davoudi Bilehsavar, Hatice Altınışık, Yusuf Turan Gül, Mustafa Oğuz, Selami Doğan, Ahmet Lütfullah Orhan","doi":"10.1080/17520363.2025.2483158","DOIUrl":null,"url":null,"abstract":"Aims: This study evaluates the association between the Intermountain Risk Score (IMRS) and coronary artery ectasia (CAE) to determine its predictive value.Materials & methods: A retrospective study was conducted at a tertiary hospital from January 2019 to January 2024. A total of 446 patients (226 with CAE, 220 controls) were included. Clinical, laboratory, and angiographic data were analyzed. IMRS was calculated based on routine demographic and laboratory parameters. Statistical analyses included logistic regression and receiver operating characteristic (ROC) curve analysis.Results: Patients with CAE had significantly higher IMRS scores (p = 0.011) and were more likely to fall into high-risk IMRS categories (p = 0.002). Smoking (HR: 3.744, p = 0.045), mean corpuscular volume (HR: 1.105, p = 0.019), and IMRS color category (HR: 5.255, p = 0.016) were independent predictors. ROC analysis showed an AUC of 0.617 for IMRS score and 0.627 for IMRS color category.Conclusions: IMRS is a significant predictor of CAE and may serve as a practical risk stratification tool. Higher-risk patients could benefit from closer monitoring and targeted interventions. Further validation in prospective studies is needed.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"295-304"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980445/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2483158","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study evaluates the association between the Intermountain Risk Score (IMRS) and coronary artery ectasia (CAE) to determine its predictive value.

Materials & methods: A retrospective study was conducted at a tertiary hospital from January 2019 to January 2024. A total of 446 patients (226 with CAE, 220 controls) were included. Clinical, laboratory, and angiographic data were analyzed. IMRS was calculated based on routine demographic and laboratory parameters. Statistical analyses included logistic regression and receiver operating characteristic (ROC) curve analysis.

Results: Patients with CAE had significantly higher IMRS scores (p = 0.011) and were more likely to fall into high-risk IMRS categories (p = 0.002). Smoking (HR: 3.744, p = 0.045), mean corpuscular volume (HR: 1.105, p = 0.019), and IMRS color category (HR: 5.255, p = 0.016) were independent predictors. ROC analysis showed an AUC of 0.617 for IMRS score and 0.627 for IMRS color category.

Conclusions: IMRS is a significant predictor of CAE and may serve as a practical risk stratification tool. Higher-risk patients could benefit from closer monitoring and targeted interventions. Further validation in prospective studies is needed.

查看原文本刊更多论文

冠状动脉扩张预测：Intermountain风险评分在识别危险患者中的作用。

目的：评价山间风险评分（Intermountain Risk Score， IMRS）与冠状动脉扩张（CAE）的相关性，以确定其预测价值。材料与方法：于2019年1月至2024年1月在某三级医院进行回顾性研究。共纳入446例患者（226例CAE， 220例对照组）。分析临床、实验室和血管造影资料。IMRS是根据常规人口统计学和实验室参数计算的。统计分析包括logistic回归和受试者工作特征（ROC）曲线分析。结果：CAE患者IMRS评分显著增高（p = 0.011），且更易落入IMRS高危类别（p = 0.002）。吸烟（HR: 3.744, p = 0.045）、平均红细胞体积（HR: 1.105, p = 0.019）和IMRS肤色分类（HR: 5.255, p = 0.016）为独立预测因子。ROC分析显示，IMRS评分的AUC为0.617，IMRS颜色类别的AUC为0.627。结论：IMRS是CAE的重要预测因子，可作为实用的风险分层工具。高风险患者可以从更密切的监测和有针对性的干预中受益。需要在前瞻性研究中进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.